Combined Targeting of BCL-2 and BCR-ABL Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem Cells

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Carter, Bing Z., Mak, Po Yee, Mu, Hong, Zhou, Hongsheng, Mak, Duncan H., Schober, Wendy, Leverson, Joel D., Zhang, Bin, Bhatia, Ravi, Huang, Xuelin, Cortes, Jorge, Kantarjian, Hagop, Konopleva, Marina, Andreeff, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5111086/
https://ncbi.nlm.nih.gov/pubmed/27605552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aag1180
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados